Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic rat model.
OBJECTIVE
It is believed that estrogen deficiency contributes importantly to the pathogenesis of menopausal metabolic syndrome and symptoms can be ameliorated with estradiol therapy. The present study reports efficacy of 17-beta estradiol encapsulated nanoparticles in treating the postmenopausal dyslipidemic condition.


METHODS
Estradiol encapsulated poly(lactide-co-glycolide) (PLGA) nanoparticles were prepared by emulsion-diffusion-evaporation method and evaluated in estrogen deficient (ovariectomized) high fat diet induced hyperlipidemic rat model.


RESULTS
The results obtained showed that estradiol nanoparticles were equally/more effective in treatment of estrogen deficient hyperlipidemic conditions at three times reduced dose and frequency in comparison to that of drug suspension administered orally.


CONCLUSIONS
Together, these results demonstrate the ability of nanoparticles in improving oral bioavailability/efficacy of estradiol.
Mittal
G
G
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
Chandraiah
G
G
Ramarao
P
P
Ravi Kumar
M N V
MN
D000818:Animals; D002784:Cholesterol / Q000097:blood; D004032:Diet; D004041:Dietary Fats / Q000494:pharmacology*; D004958:Estradiol / Q000008:administration & dosage* / Q000494:pharmacology*; D005260:Female; D006949:Hyperlipidemias / Q000378:metabolism*; D019344:Lactic Acid; D053758:Nanoparticles; D010052:Ovariectomy; D010316:Particle Size; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D017207:Rats, Sprague-Dawley; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D004041:Dietary Fats; D017392:Thiobarbituric Acid Reactive Substances; D014280:Triglycerides; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D004958:Estradiol; D002784:Cholesterol
Pharm Res. 1997 Mar;14(3):259-66
9098866
Biogerontology. 2006 Apr;7(2):91-100
16802112
Curr Control Trials Cardiovasc Med. 2001;2(5):211-214
11806798
Int J Obes Relat Metab Disord. 2002 Mar;26(3):335-43
11896488
Lipids. 2008 Mar;43(3):231-41
18196308
Annu Rev Pharmacol Toxicol. 1996;36:203-32
8725388
Free Radic Biol Med. 1996;20(5):707-27
8721615
J Control Release. 2007 May 14;119(1):77-85
17349712
Eur J Pharm Biopharm. 2007 Sep;67(2):361-9
17452099
Am J Epidemiol. 2003 Apr 15;157(8):701-11
12697574
Endocrinology. 1997 Apr;138(4):1552-8
9075715
Clin Sci (Lond). 2002 Feb;102(2):151-66
11834135
J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):271-8
15993048
Drug Discov Today Technol. 2005 Spring;2(1):75-81
24981758
Clin Chem. 2006 Apr;52(4):601-23
16484333
Metabolism. 1992 Oct;41(10):1110-4
1328822
Anal Biochem. 1979 Jun;95(2):351-8
36810
J Pharm Sci. 2008 Apr;97(4):1530-42
17722098
Arterioscler Thromb Vasc Biol. 2000 Jul;20(7):1817-23
10894823
J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):387-93
11162949
Am J Hypertens. 2001 Jun;14(6 Pt 2):186S-193S
11411755
Pharm Res. 2006 Jan;23(1):184-95
16267632
Maturitas. 1998 Sep 20;30(1):5-9
9819777
Prog Cardiovasc Dis. 1995 Nov-Dec;38(3):199-210
7494882
Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422
15719481
Maturitas. 1999 Dec 15;33(3):259-69
10656504
Metabolism. 2006 May;55(5):605-13
16631436
Am J Obstet Gynecol. 1995 Sep;173(3 Pt 2):982-9
7573295
Free Radic Biol Med. 1992 Oct;13(4):341-90
1398217
Best Pract Res Clin Obstet Gynaecol. 2002 Jun;16(3):329-55
12099666
Adv Drug Deliv Rev. 1998 Dec 1;34(2-3):135-154
10837675
N Engl J Med. 1996 Aug 15;335(7):453-61
8672166
Int J Cardiol. 2004 Dec;97(3):485-93
15561337
Pharmacol Res. 2005 Oct;52(4):313-20
15979893
J Control Release. 2006 May 1;112(1):1-14
16530874
Maturitas. 2002 Aug 30;43 Suppl 1:S3-10
12361883
Prev Med. 1991 Jan;20(1):47-63
1826173